细胞凋亡
生物标志物
生物
胎儿游离DNA
癌症
癌症研究
医学
遗传学
胎儿
产前诊断
怀孕
作者
Ellen Heitzer,Lisa Auinger,Michael R. Speicher
标识
DOI:10.1016/j.molmed.2020.01.012
摘要
Cell-free DNA (cfDNA) is evolving into a widely used prognostic and predictive biomarker, particularly in oncology. However, its versatile clinical use precedes a profound understanding of the underlying biology of cfDNA release. There is much evidence to suggest that cfDNA is mainly derived from dying (i.e., apoptotic) cells. However, numerous cancer studies have shown that cfDNA is informative about acquired resistance to given therapies, which is present in living, proliferating tumor subclones. To explain this contradiction, we review current insights regarding cfDNA release, in particular the interplay between apoptosis and proliferation. We describe how improved knowledge about cfDNA biology could be used for novel therapeutic strategies and how this may affect patient management.
科研通智能强力驱动
Strongly Powered by AbleSci AI